Broad spectrum Gram-positive and Gram-negative organisms (building on Third Generation Cephalosporin coverage) Beta-Lactamase resistant organisms More AmpB beta lactamase resistant than second and Third Generation Cephalosporins Better activity against Citrobacter and Enterobacter Pseudomonas coverage (similar to...
In addition, Cefepime has higher Gram-negative coverage and more stable resistance to beta-lactamases than third-generation cephalosporins. It penetrates the cell walls of Gram-negative bacteria more rapidly. This is the reason why cefepime covers a wider range of Gram-negative bacteria than third-g...
Sign up with one click: Facebook Twitter Google Share on Facebook cefepime Dictionary Wikipedia Related to cefepime:Cefixime [sef´ĕpēm] a semisynthetic fourth-generationcephalosporinantibiotic; used in the treatment of infections of the skin and soft tissues and of the respiratory and urinary tr...
Cefepime has increased gram-negative coverage and is more stable against beta-lactamases when compared to third-generation cephalosporins due to a few mechanisms. One such mechanism is that penicillin-binding enzymes have a lower affinity for cefepime. Another difference is that the chemical structure ...
Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. We did a systematic review of randomise... D Yahav,M Paul,A Fraser,... - 《Lancet Infectious Diseases》 被引量: 354发表: 2007年 Pharmacodynamics of once-daily amikacin in various...
Cefepime is a semi-synthetic fourth generation cephalosporin with broader Gram-positive and excellent Gram-negative bacterial coverage. Its extended anti-microbial activity and infrequent tendency to develop resistance makes it popular for treatment of infections due to multi-drug resistant organisms. It ...
Efficacy and safety of cefepime: a systematic review and meta-analysis Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. We did a systematic review of randomise... D Yahav,M Paul,A Fraser,... - 《Lancet Infectious Diseases》 被...
Vaborbactam possesses a more limited inhibitory profile that does not include OXA-48 carbapenemases (44); therefore, incomplete coverage of OXA-48-producing CRE by meropenem-vaborbactam is the reflection of the unprotected meropenem activity. Ceftazidime-avibactam and cefepime-taniborbactam showed ...
On the other hand, if one postulates an MIC of 8 mg/l, which was associated with treatment failures in patients with bacteremia due to Gram negative pathogens [6], then close to 50% of the patients would have had an inappropriate coverage (T>MIC > 50%). This is of particular concern...
Effective empiric treatment of pneumonia requires antibiotic coverage against gram-negative and gram-positive pathogens, including drug-resistant isolates... J Borja,F Jané - 《Antimicrobial Agents & Chemotherapy》 被引量: 62发表: 1999年 A multicenter randomized trial of prophylaxis with intravenous ce...